---
title: "The CEO of GSK stated that they are having very constructive communications with the U.S. government"
description: "The CEO of GSK stated that they are having very constructive communications with the U.S. government regarding drug pricing issues, but declined to comment on specific situations"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263253947.md"
published_at: "2025-10-29T09:44:17.000Z"
---

# The CEO of GSK stated that they are having very constructive communications with the U.S. government

> The CEO of GSK stated that they are having very constructive communications with the U.S. government regarding drug pricing issues, but declined to comment on specific situations

The CEO of GSK stated that they are having very constructive discussions with the U.S. government regarding drug pricing issues but declined to comment on specific situations

### Related Stocks

- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSK Begins Up to GBP450 Million Share Buyback Tranche | GSK Begins Up to GBP450 Million Share Buyback Tranche | [Link](https://longbridge.com/en/news/276103252.md) |
| GSK Recieves Approval For Exdensur From The European Commission | GSK plc :GSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONGSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | [Link](https://longbridge.com/en/news/276102835.md) |
| Exdensur approved in EU for severe asthma and CRSwNP | GSK has received European Commission approval for Exdensur (depemokimab), the first ultra-long-acting biologic for sever | [Link](https://longbridge.com/en/news/276226507.md) |
| GSK's Exdensur Approved in EU as Add-on Treatment for Severe Asthma, Chronic Rhinosinusitis | GSK's Exdensur Approved in EU as Add-on Treatment for Severe Asthma, Chronic Rhinosinusitis | [Link](https://longbridge.com/en/news/276103226.md) |
| Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK) | Berenberg Bank analyst Kerry Holford has maintained a Hold rating on GlaxoSmithKline (GSK) with a price target of £20.00 | [Link](https://longbridge.com/en/news/276103203.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.